Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
orelabrutinib + rituximab + carmustine + etoposide + cytarabine + melphalan
- Development stage
- Unknown
- Lead developer
- InnoCare Pharma
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This combination therapy is a treatment regimen being evaluated in a Phase 2 clinical trial at Ruijin Hospital for treatment-naive, non-high-risk mantle cell lymphoma (MCL). The protocol consists of induction therapy with **orelabrutinib** (a potent, irreversible Bruton's tyrosine kinase inhibitor developed by InnoCare Pharma) and **rituximab** (a CD20-directed monoclonal antibody), followed by optional autologous stem cell transplantation (ASCT). Patients undergoing ASCT receive the **BEAM** conditioning regimen, which includes the alkylating agents **carmustine** and **melphalan**, the topoisomerase II inhibitor **etoposide**, and the antimetabolite **cytarabine**. The regimen is designed to maximize complete response rates by combining targeted B-cell signaling inhibition with immune-mediated depletion and high-dose chemotherapy-mediated cytoreduction.
- Other names
- BEAM-Ruijin Hospital-mantle cell lymphomaorelabrutinib + rituximab + BEAMorelabrutinib + rituximab with ASCT
02
Targets
CD20 (B-lymphocyte antigen CD20)DNADNA polymerase familyTOP2A (DNA topoisomerase II)BTK (Bruton tyrosine kinase)
Beyond the preview
Go deeper on orelabrutinib + rituximab + carmustine + etoposide + cytarabine + melphalan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on orelabrutinib + rituximab + carmustine + etoposide + cytarabine + melphalan.